Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00089180
Other study ID # NCI-2012-02619
Secondary ID UAB-0323CDR00003
Status Completed
Phase Phase 2
First received August 4, 2004
Last updated December 3, 2015
Start date March 2004

Study information

Verified date June 2013
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This randomized phase II trial is studying how well T4N5 liposomal lotion works in preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant. Chemoprevention therapy is the use of certain drugs to try to prevent the development of or recurrence of cancer. T4N5 liposomal lotion may be effective preventing the recurrence of nonmelanoma skin cancer in patients who have undergone a kidney transplant.


Description:

PRIMARY OBJECTIVES:

I. Compare the incidence of nonmelanoma skin cancer (NMSC) (average per patient) on the sun-exposed skin of renal transplant recipients with a history of NMSC treated with T4N5 liposomal lotion vs placebo.

SECONDARY OBJECTIVES:

I. Compare the proportion of these patients who develop NMSC on sun-exposed skin during treatment and after cessation of treatment with these regimens.

II. Compare the incidence of NMSC on the sun-exposed skin of these patients after cessation of treatment with these regimens.

III. Compare the incidence of recurrent and de novo actinic keratoses (AKs) in patients treated with these regimens.

IV. Determine whether either of these regimens induces regression of AKs left untreated on the sun-exposed skin of these patients.

V. Compare the proportion of these patients who develop melanoma, in both treated and untreated sites, during and after cessation of treatment with these regimens.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to study center. Patients are randomized to 1 of 2 arms.

Six months before randomization, lesions suspicious for nonmelanoma skin cancer (NMSC) are surgically removed and histologically analyzed. All but 10 randomly selected non-suspicious lesions are removed. Of these 10 lesions, 5 are shave biopsied immediately pre-treatment for histologic and surrogate endpoint biomarker (SEB) analysis and to determine a baseline actinic keratosis: wart ratio. Patients also undergo a pre-treatment biopsy of normal appearing sun-exposed and non-sun-exposed skin (buttocks).

Arm I: Patients apply T4N5 liposomal lotion topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.

Arm II: Patients apply placebo topically to non-occluded, sun-exposed areas of the head, neck, face, and upper extremities once daily for 12 months.

Treatment in both arms continues in the absence of the development of metastatic cutaneous squamous cell cancer or melanoma. Patients are followed every 3 months.

PROJECTED ACCRUAL: A total of 100 patients (50 per treatment arm) will be accrued for this study within 6 months.


Recruitment information / eligibility

Status Completed
Enrollment 100
Est. completion date
Est. primary completion date January 2007
Accepts healthy volunteers No
Gender Both
Age group 19 Years and older
Eligibility Inclusion Criteria:

- History of histologically confirmed nonmelanoma skin cancer

- Renal transplant recipient = 4 years ago

- Currently receiving standard multi-agent pharmacologic immunosuppression

- Fitzpatrick skin type I, II, or III

- Sun-damaged skin with = 10 lesions consistent with actinic keratoses OR wart on the upper extremities (arms, forearms, hands), neck, face, and exposed scalp combined

- No history of keloid formation

- No known photosensitivity disorder

- No history of malignant melanoma

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- No diagnosis of acute allograft rejection within the past 30 days requiring an increase in immunosuppression

- No invasive malignancy within the past 4 years except curatively excised NMSC, cured polyclonal posttransplantation lymphoproliferative disease, carcinoma in situ of the cervix, stage 0 chronic lymphocytic leukemia, unless all of the following criteria are met:

- No current evidence of disease

- No treatment for the invasive malignancy within the past 6 months

- No concurrent or planned therapy for the invasive malignancy

- Has an expected disease-free survival of at least 5 years

- No diagnosis of melanoma or melanoma in situ

- No other medical or psychosocial condition that would preclude study participation

- No likelihood, in the opinion of the transplant surgeon/nephrologist, to experience graft loss and/or discontinue standard immunosuppressive therapy during study treatment

- More than 30 days since prior and no concurrent topical chemotherapy (including topical fluorouracil) to areas being studied

- No concurrent topical preparations containing corticosteroids

- More than 30 days since prior and no concurrent local radiotherapy to a study area

- More than 30 days since prior and no concurrent cryotherapy to target lesions

- No prior or concurrent experimental immunosuppressive agents

- More than 30 days since prior investigational medication

- More than 30 days since prior and no concurrent systemic psoralens or retinoids

- More than 60 days since prior and no concurrent laser resurfacing, dermabrasion, or chemical peels to a study area

- No other concurrent investigational agents

- No other concurrent topical medications, including prescription and over the counter preparations, to the areas being studied (e.g., upper arms, forearms, neck, face, and scalp)

- Concurrent moisturizer, emollient, and sunscreen allowed

- No concurrent topical preparations containing vitamin A derivatives

- No concurrent nonsteroidal anti-inflammatory drugs

- Concurrent cardioprotective doses of aspirin (< 100 mg/day) allowed

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention


Intervention

Drug:
liposomal T4N5 lotion
Given topically
Other:
placebo
Given topically
laboratory biomarker analysis
Correlative studies

Locations

Country Name City State
United States UAB Comprehensive Cancer Center Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of nonmelanoma skin cancer (NMSC) Descriptive statistics such as mean, median, standard deviation will be calculated to summarize the number of new NMSC for each of the two randomization arms and compared using the Wilcoxon rank-sum test. Up to 18 months No
Secondary Proportion of patients who develop NMSC during and after completion of study therapy Calculated for the study drug and placebo arms and compared using the Fisher's exact or chi-square test. Up to 18 months No
Secondary Incidence of NMSC Summarized by treatment arm and compared using the Wilcoxon rank-sum test. Up to 18 months No
Secondary Incidence of recurrent and de novo actinic keratoses (AKs) after completion of study therapy Summarized by treatment arm and compared using the Wilcoxon rank-sum test. Similarly, multivariate Poisson regression model will be utilized to compare the cumulative number of incident AKs at the end of treatment as a function of treatment arm and covariates. Up to 18 months No
Secondary Number of regressed AKs after completion of study therapy Summarized by treatment group and compared using the Wilcoxon rank-sum test. Similarly, multivariate Poisson regression model will be utilized to compare the cumulative number of regressed AKs at the end of treatment as a function of treatment group and covariates. In addition to the covariates listed above, the number of AKs at baseline will be included as a covariate in the model. At 18 months No
Secondary Risk of developing melanoma in both treated and untreated sites The data will be collected and analyzed by scoring both total body melanoma distribution and those in lotion treatment sites. Relative risk will be calculated for the development of melanomas. The Chi-Square test will be used to explore the risk relationships. Up to 18 months No
Secondary Change in SEBs levels Descriptive statistics will be calculated at baseline and end of treatment for several SEBs by treatment arm. The change in SEB levels will be also calculated for each patient and compared between treatment arms using either the two-sample t-test or Wilcoxon rank-sum test. From baseline to 12 months No
See also
  Status Clinical Trial Phase
Recruiting NCT03013647 - Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization N/A
Completed NCT02674048 - Metvix Daylight PDT in Actinic Keratosis
Completed NCT02239679 - Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy Phase 2
Completed NCT02421471 - PMS to Evaluate the Safety and Efficacy of Picato® Gel
Completed NCT01686152 - Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Phase 3
Terminated NCT01525329 - Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease Phase 3
Completed NCT01444989 - Development and Validation of a Quality of Life Instrument for Actinic Keratosis N/A
Completed NCT01449513 - PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy Phase 1
Terminated NCT01203878 - Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy Phase 4
Completed NCT00989313 - A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study Phase 3
Completed NCT00306800 - Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp Phase 3
Completed NCT00375739 - Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses Phase 2
Completed NCT03285490 - A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004) Phase 3
Completed NCT03319251 - Biomarker Database Registry for Photodynamic Therapy
Completed NCT02866695 - Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients Phase 4
Completed NCT02952898 - Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses Phase 3
Completed NCT02984072 - Menthol for PDT Pain Relief Phase 4
Recruiting NCT03684772 - Topical Ionic Contra-Viral Therapy in Actinic Keratosis Phase 2
Completed NCT02878382 - Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT N/A
Completed NCT02938715 - Pilot Study of the Pragmatic Use of Mobile Phone Based Follow up of Actinic Keratoses Treated With Topical 5-fluorouracil N/A